In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 8 ( 2021-8-2), p. e0254628-
Abstract:
Most current clinical vaccines work primarily by inducing the production of neutralizing antibodies against pathogens. Vaccine adjuvants that efficiently induce T cell responses to protein antigens need to be developed. In this study, we developed a new combination adjuvant consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), D35, and an aluminum salt. Among the various combinations tested, the DOTAP/D35/aluminum salt adjuvant induced strong T cell and antibody responses against the model protein antigen with a single immunization. Adjuvant component and model antigen interaction studies in vitro also revealed that the strong mutual interactions among protein antigens and other components were one of the important factors for this efficient immune induction by the novel combination adjuvant. In addition, in vivo imaging of the antigen distribution suggested that the DOTAP component in the combination adjuvant formulation elicited transient antigen accumulation at the draining lymph nodes, possibly by antigen uptake DC migration. These results indicate the potential of the new combination adjuvant as a promising vaccine adjuvant candidate to treat infectious diseases and cancers.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0254628
DOI:
10.1371/journal.pone.0254628.g001
DOI:
10.1371/journal.pone.0254628.g002
DOI:
10.1371/journal.pone.0254628.g003
DOI:
10.1371/journal.pone.0254628.g004
DOI:
10.1371/journal.pone.0254628.g005
DOI:
10.1371/journal.pone.0254628.g006
DOI:
10.1371/journal.pone.0254628.s001
DOI:
10.1371/journal.pone.0254628.s002
DOI:
10.1371/journal.pone.0254628.s003
DOI:
10.1371/journal.pone.0254628.s004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Bookmarklink